Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers
about
Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumorsKRAS Mutant Pancreatic Cancer: No Lone Path to an Effective TreatmentGenetic profiling of intrahepatic cholangiocarcinoma and its clinical implication in targeted therapyMEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapySimilar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistanceChemical Disruption of Wnt-dependent Cell Fate Decision-making Mechanisms in Cancer and Regenerative MedicineCombination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done YetTen things you should know about protein kinases: IUPHAR Review 14Central role of Snail1 in the regulation of EMT and resistance in cancer: a target for therapeutic interventionPathways and therapeutic targets in melanomaCIViC databaseOptimization of diarylthiazole B-raf inhibitors: identification of a compound endowed with high oral antitumor activity, mitigated hERG inhibition, and low paradoxical effectSmall molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signallingLoss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.Targeting the VEGF-C/VEGFR3 axis suppresses Slug-mediated cancer metastasis and stemness via inhibition of KRAS/YAP1 signalingTargeting pathways downstream of KRAS in lung adenocarcinoma.Survey of phosphorylation near drug binding sites in the Protein Data Bank (PDB) and their effects.Molecular pathways and therapeutic targets in lung cancerNovel drugs that target the estrogen-related receptor alpha: their therapeutic potential in breast cancerClinical responses to ERK inhibition in BRAFV600E-mutant colorectal cancer predicted using a computational model.Insights into the binding mode of MEK type-III inhibitors. A step towards discovering and designing allosteric kinase inhibitors across the human kinomeTreatment of NRAS-mutated advanced or metastatic melanoma: rationale, current trials and evidence to dateMolecular pathways: targeting NRAS in melanoma and acute myelogenous leukemia.Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas.BRAF kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wild-type RAS.Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.A combination therapy for KRAS-driven lung adenocarcinomas using lipophilic bisphosphonates and rapamycinDrugging the undruggable RAS: Mission possible?Impact of the mitogen-activated protein kinase pathway on the subproteome of detergent-resistant microdomains of colon carcinoma cells.Inhibition of mitogen-activated protein kinase pathway can induce upregulation of human leukocyte antigen class I without PD-L1-upregulation in contrast to interferon-γ treatment.Towards pathway-centric cancer therapies via pharmacogenomic profiling analysis of ERK signalling pathwayThe Mutant KRAS Gene Up-regulates BCL-XL Protein via STAT3 to Confer Apoptosis Resistance That Is Reversed by BIM Protein Induction and BCL-XL AntagonismTargeting drivers of melanoma with synthetic small molecules and phytochemicals.Small-molecule inhibitors of ERK-mediated immediate early gene expression and proliferation of melanoma cells expressing mutated BRafMEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms.Cytotoxicity of PEGylated liposomes co-loaded with novel pro-apoptotic drug NCL-240 and the MEK inhibitor cobimetinib against colon carcinoma in vitro.Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts.Targeted inhibition of metastatic melanoma through interference with Pin1-FOXM1 signaling.
P2860
Q24294914-D30947EE-08F1-4B70-AB49-F84A5A6529DEQ26751520-D836C8C1-55E9-4D6F-BAE4-98089867C04AQ26751655-8CE142C0-9417-41D4-A6EA-CCA240010902Q26771192-331EA4FC-8B50-4278-8873-52ECFB36D297Q26795609-50569673-75BD-4AAB-ADAA-340E35718558Q26796673-A7CFE15E-75DB-4513-A48E-9A5F0B2B4621Q26799864-70ED2ECE-F386-4D3B-870A-2573E6D0C797Q26849417-735C37F1-F2E1-41EF-AEF5-34B6822AD9A5Q26864839-5A400277-3F14-43F9-9B96-5B6910F161BAQ26865736-6A33A6E3-E807-45EF-BA5B-7CEF0E72458AQ27612411-6AA18F43-E2D1-45DE-8103-1FC8E63915C2Q27696222-FD5E4926-B8A9-48D5-9B58-679A56F5897FQ27727733-2514108F-55EC-4517-9BCC-6EB0623D5FA8Q27852894-A50B7174-0FF9-4B2F-8266-BDC6DE54B70EQ27853021-A9F33CE6-848D-42B5-A39A-9DABE6219AAFQ27853310-68C537F6-1F91-405C-925C-C20F403C08C0Q28078716-C1B02421-321D-40E6-A012-F4CBB1C27EA0Q30597330-DCADB40C-0802-4031-B029-8046FA31D472Q30821888-0B896BAC-7187-4CDF-9A22-0F15F3743F05Q33688872-8F67EF32-71C5-40DB-88E5-5F0C33D0C2A7Q33698278-1E5CB16F-59C1-4084-AC41-594B7F3C3E44Q33767369-B3E4759D-C3D9-493C-AE4F-995476FF54D9Q33811883-DFEB9133-7432-48B5-ADF2-A01668A0D7D5Q33887664-93D02E31-DAC2-4BE5-AC0B-09017D9220A4Q34052520-98CD64F7-5C16-42A9-AEDB-FD74C9B49EFFQ34193749-F933DB7C-88F8-4800-8269-C7E4EA7D9E1BQ34393208-E870076C-1ED0-45E8-9E87-0F8CC1A4DC8CQ34662946-12C3C2F2-C492-4DE9-8603-327181679C23Q35078290-C7B49147-4E56-4F60-91DF-73CE5306983DQ35163434-21BEF96C-C141-483C-865C-2E6C31ABDD38Q35379875-4A55E563-A9DF-4DB0-9B74-A89D1521418DQ35713265-40D38FB8-0279-42CE-8F22-6DB6BD95E410Q35897673-F148B5D5-FA9B-44A7-8B9B-101BBF1D703CQ36092931-588EFA62-8A13-4A73-95BA-591631B6D4EBQ36141097-50D80A4C-7D6C-4E41-BF44-948A7AFA4234Q36276136-976A82CF-AE50-40E7-819C-A8860D8BDF2AQ36328021-376F4A4C-BC18-4D0E-9460-08C1AE7215B9Q36396095-9E0F214F-8478-4669-B498-4482E5EE715FQ36544152-F94D2B61-62C7-40A0-B193-BFB891255A56Q36590628-4DB9C206-3161-480E-A641-B9504009DB55
P2860
Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers
description
2013 nî lūn-bûn
@nan
2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
name
Mechanism of MEK inhibition de ...... AS- versus BRAF-driven cancers
@ast
Mechanism of MEK inhibition de ...... AS- versus BRAF-driven cancers
@en
Mechanism of MEK inhibition de ...... AS- versus BRAF-driven cancers
@nl
type
label
Mechanism of MEK inhibition de ...... AS- versus BRAF-driven cancers
@ast
Mechanism of MEK inhibition de ...... AS- versus BRAF-driven cancers
@en
Mechanism of MEK inhibition de ...... AS- versus BRAF-driven cancers
@nl
prefLabel
Mechanism of MEK inhibition de ...... AS- versus BRAF-driven cancers
@ast
Mechanism of MEK inhibition de ...... AS- versus BRAF-driven cancers
@en
Mechanism of MEK inhibition de ...... AS- versus BRAF-driven cancers
@nl
P2093
P2860
P50
P3181
P356
P1433
P1476
Mechanism of MEK inhibition de ...... AS- versus BRAF-driven cancers
@en
P2093
Christine Orr
Georgia Hatzivassiliou
Huifen Chen
Jacob R Haling
Joanne F M Hewitt
Jocelyn Chan
Klaus P Hoeflich
Kyung Song
Lori S Friedman
Marcia Belvin
P2860
P2888
P304
P3181
P356
10.1038/NATURE12441
P407
P577
2013-08-11T00:00:00Z
P5875
P6179
1027112082